Navigation Links
BioAnalytix advances the biologic drug development
Date:6/11/2014

Biologic drugs are highly complex, but they may be the answer to many medical illnesses and conditions that currently have no treatment available. The problem is, these drugs are not easy to characterize and test. Unlike most drugs that are chemically synthesized, biological products are protein-based and biologically produced. This means the drug development and testing stages are often much longer and more complex.

To answer this need, Northeastern University's College of Science and the Barnett Institute launched BioAnalytix two years ago. Led by CEO Kirtland Poss, BioAnalytix is now filling a critical gap in the area of biologic drug development and launch. "What we do is unique and in demand," said Poss. "There is a lot of complexity to biologic drugs, and they need precise characterization throughout the development process and it's hard to do."

For the past 10 years, the Barnett Institute has been applying its characterization techniques to biologic drugs in early stage development. In 2012, BioAnaytix was formed to help with the later-stage development decisions and regulatory filings for these cutting-edge drugs.

Currently, BioAnalytix is working with leading pharmaceutical companies in the U.S, Europe, and Asia, typically on later stage drug development. This is the stage where a biologic drug looks promising, and the drug company is looking to move on to Phase 3 clinical trials or regulatory approvalsthe final stages before going on the market.

Over the past year, BioAnalytix has made some very significant progress. The company is hiring an industry-seasoned CFO, and has also moved to Cambridge, where it is surrounded by many leading pharmaceutical companies, but is still close to its original home, the Barnett Institute.

"BioAnaytix will continue to maintain and grow its affiliation with Northeastern University and the Barnett, because it is a very natural and real win for both of us," said Poss. "They benefit from more exposure to pharmaceutical companies, and we benefit from exposure to cutting-edge innovation and early stage research that is truly world-leading in these areas. As we grow, this will continue to benefit both."


'/>"/>

Contact: Lori Lennon
l.lennon@neu.edu
617-680-5129
Northeastern University College of Science
Source:Eurekalert

Related medicine news :

1. Northeasterns Barnett Institute announces formation of leading analytics company, BioAnalytix, LLC
2. Major advances in breast, prostate, colorectal cancer featured at ASCO Annual Meeting
3. EuroPCR 2014 showcases technological advances in complex cardiovascular interventions
4. Molecule linked to aggressive pancreatic cancer offers potential clinical advances
5. Space-tested fluid flow concept advances infectious disease diagnoses
6. Smartphone app reads blood oxygen levels to hospital standards, advances to global obstetrics tests
7. Autism Speaks study finds advances towards universal early screening
8. WesternU Team Advances Understanding of Mechanisms of Learning and Neural Degeneration
9. New Advances in Oral Technology from Henning Family Dental in Spokane Create Comfort for Anxious Patients
10. Enterprises TV Introduces New Series on Nutritional Advances
11. Autism Speaks announces top 10 advances in autism research 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... NJ (PRWEB) , ... December 08, 2016 , ... CURE ... cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to ... making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... 08, 2016 , ... Today’s patients are encouraged to be ... SIGVARIS has created a new line of anti-embolism stockings to help prevent a ... benefits of graduated compression when transitioning from recovery to early rehabilitation. , The ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research and Markets ... Report" report to their offering. ... This report analyzes the worldwide markets for ... US, Canada , Japan , ... , and Rest of World. Annual estimates and forecasts are provided ...
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX , ... Nationwide Children,s Hospital signed a membership agreement ... the development of new cures. The ... over 57 million patients globally, biopharmaceutical companies and ... to improve protocol design, site selection, patient recruitment, ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology: